Literature DB >> 24566336

The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: study design, data analysis, interpretation.

Hervé Lebrec1, Brigitte Molinier2, Darrell Boverhof3, Mark Collinge4, Wendy Freebern5, Kristin Henson6, Daniel T Mytych7, Hans D Ochs8, Ronald Wange9, Yung Yang10, Lei Zhou7, Joshua Arrington11, Marie Soleil Christin-Piché12, Jacintha Shenton13.   

Abstract

The T-cell-dependent antibody response (TDAR) assay is a measure of immune function that is dependent upon the effectiveness of multiple immune processes, including antigen uptake and presentation, T cell help, B cell activation, and antibody production. It is used for risk and safety assessments, in conjunction with other toxicologic assessments, by the chemical and pharmaceutical industries, and research and regulatory agencies. It is also employed to evaluate investigational drug efficacy in animal pharmacology studies, provide evidence of biological impact in clinical trials, and evaluate immune function in patients with primary or secondary immunodeficiency diseases. Various immunization schemes, analytical methods, approaches to data analysis, and data interpretations are in use. This manuscript summarizes some recommended practices for the conduct and interpretation of the assay in animal studies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunotoxicity; Nonclinical studies; TDAR

Mesh:

Year:  2014        PMID: 24566336     DOI: 10.1016/j.yrtph.2014.02.008

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  4 in total

1.  Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens.

Authors:  Miriam N Jacobs; Annamaria Colacci; Raffaella Corvi; Monica Vaccari; M Cecilia Aguila; Marco Corvaro; Nathalie Delrue; Daniel Desaulniers; Norman Ertych; Abigail Jacobs; Mirjam Luijten; Federica Madia; Akiyoshi Nishikawa; Kumiko Ogawa; Kiyomi Ohmori; Martin Paparella; Anoop Kumar Sharma; Paule Vasseur
Journal:  Arch Toxicol       Date:  2020-06-27       Impact factor: 5.153

2.  Strain differences in histopathological features of lymphoid tissues of SD and F344 rats in a T cell-dependent antibody response assay of cyclophosphamide.

Authors:  Bunichiro Ogawa; Yutaka Nakanishi; Tomoko Koyama; Kazunori Arima; Minoru Sasaki
Journal:  J Toxicol Pathol       Date:  2019-04-07       Impact factor: 1.628

3.  Development of a nonhuman primate challenge model to evaluate CD8+ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors.

Authors:  Richard Graveline; Morad Haida; Carolyne Dumont; Dominic Poulin; Florence Poitout-Belissent; Rana Samadfam; Sven Kronenberg; Franziska Regenass-Lechner; Rodney Prell; Marie-Soleil Piche
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

4.  Immunotoxicity of Per- and Polyfluoroalkyl Substances: Insights into Short-Chain PFAS Exposure.

Authors:  Tracey Woodlief; Samuel Vance; Qing Hu; Jamie DeWitt
Journal:  Toxics       Date:  2021-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.